Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Szilvia Lovas"'
Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary
Autor:
Szilvia Lovas, Nóra Obajed Al-Ali, Gergely Varga, Virág Szita, Hussain Alizadeh, Márk Plander, Péter Rajnics, Árpád Illés, Zsuzsa Szemlaky, Gábor Mikala, László Váróczy
Publikováno v:
Pathology and Oncology Research, Vol 28 (2022)
Pomalidomide is a third generation immunomodulatory drug in the treatment of refractory and relapsed multiple myeloma patients. Our aim was to investigate the efficacy and safety of pomalidomide therapy in a real world setting. Eighty-six Hungarian p
Externí odkaz:
https://doaj.org/article/108b0d10eefe48f3bdd373b674f12ec2
Autor:
Viktor Lakatos, Anna Herczku, Gabor Mikala, Szilvia Lovas, László Váróczi, Hussain Alizadeh, Ádám Ónodi, Szabolcs Modok
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S53
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6e6944bcab1681bb7c1ef2b7c54a39e
https://doi.org/10.1016/s2152-2650(22)00362-7
https://doi.org/10.1016/s2152-2650(22)00362-7
Autor:
Szabolcs Modok, Tamás Schneider, Szilvia Lovas, Gabor Mikala, Krisztina Kórád, Zsolt Nagy, Tamás Masszi, Beáta Deák, G. Radványi, László Váróczy, János Rottek, Márk Plander, Júlia Gaál-Weisinger, Tamás Szendrei, Annamária Rencsik, Péter Rajnics, Gergely Varga, Hussain Alizadeh, Zoltán Csukly, Apor Hardi, Szabolcs Kosztolányi, Elvira Altai, Árpád Illés, András Tóth, Zsuzsanna Lengyel, Zoltán Kohl, Virág Réka Szita, Zita Borbényi, Erika Szaleczky
Publikováno v:
Pathology and Oncology Research
In Hungary, the cost of lenalidomide-based therapy is covered only for relapsed multiple myeloma (MM) patients, therefore lenalidomide is typically used in the second-line either as part of a triplet with proteasome inhibitors or as a doublet. Lenali
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70943bef899353eebf4a3fd88676af76
http://europepmc.org/articles/PMC8262242
http://europepmc.org/articles/PMC8262242
Autor:
Zsuzsanna Kurti, Fanni Rencz, Tamás Cserni, Károly Palatka, Szilvia Lovas, János Banai, Márta Péntek, Tamás Molnár, László Herszényi, Peter L. Lakatos, László Gulácsi, Valentin Brodszky
Publikováno v:
Quality of Life Research. 28:141-152
The EuroQol five-dimension questionnaire (EQ-5D) is the most commonly used instrument to obtain utility values for cost-effectiveness analyses of treatments for Crohn’s disease (CD). We aimed to compare the measurement properties of the two adult v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5725b3ec89c104a3afb2ef1e686c221f
https://doi.org/10.1007/s11136-018-2003-4
https://doi.org/10.1007/s11136-018-2003-4
Autor:
Gábor Mikala, Tamás Masszi, Erika Szaleczky, Gergely Varga, Árpád Illés, László Rejtő, Nóra Adamkovich, Otto Csacsovszki, Márk Plander, Hussain Alizadeh, Péter Rajnics, Zoltán Csukly, Tamás Schneider, Miklos Egyed, Zsolt Nagy, Krisztina Wolf, Nikolett Wohner, Szilvia Lovas, Ágnes Bereczki, Péter Farkas, László Váróczy, Árpád Szomor, Tamás Szendrei, Zita Borbényi
Publikováno v:
International journal of hematology. 110(5)
Daratumumab is a human anti-CD38 monoclonal antibody used in the treatment of refractory and relapsed multiple myeloma. We investigated the efficacy and safety of daratumumab therapy in a real-world setting. Ninety-nine Hungarian patients were includ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0eecac2e0821f9f6a171fc1b53ebfb1
https://pubmed.ncbi.nlm.nih.gov/31392600
https://pubmed.ncbi.nlm.nih.gov/31392600
Autor:
Szilvia Lovas, Zoltán Szepes, Anna Fábián, Karin Malickova, Ferenc Nagy, Károly Palatka, Katarina Mitrova, Ágnes Milassin, Milan Lukas, Martin Bortlik, Veronika Hruba, Klaudia Farkas, Zsuzsanna Kurti, Kata Szántó, Mariann Rutka, Ágnes Anna Csontos, Peter L. Lakatos, Tamás Molnár, Martin Lukas, Martin Kolar, Pál Miheller, Zsuzsanna Vegh, Dana Duricova, Anita Bálint, Renáta Bor, Tibor Nyári
Publikováno v:
Expert opinion on biological therapy. 18(11)
CT-P13, the first biosimilar monoclonal antibody to infliximab (IFX), has previously been confirmed to be efficacious in inducing mucosal healing in ulcerative colitis (UC) patients. The aim of this study was to evaluate the efficacy of CT-P13 therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5837e2788b37534bc70585504781c91a
https://pubmed.ncbi.nlm.nih.gov/30277084
https://pubmed.ncbi.nlm.nih.gov/30277084
FDG PET-CT is a global, noninvasive, sensitive method to determine the location and activity of inflammatory lesions. Segmental FDG uptake is proportional with immune cell infiltration of bowel. Our aim was to evaluate prospectively the role of PET i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fc2a185be51f6a7f349f8de578ba4fc
Autor:
Kata Szántó, Klaudia Farkas, Imre Földesi, T Molnár, Ágnes Milassin, Anita Bálint, Z A Mezei, Károly Palatka, Anna Fábián, András Lajos Szijártó, D Kata, Renáta Bor, Szilvia Lovas, Zoltán Szepes, Mariann Rutka
Publikováno v:
Journal of Crohn's and Colitis. 12:S356-S356
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f4f98c7e7defc49d1a0f9e96d623382
https://doi.org/10.1093/ecco-jcc/jjx180.622
https://doi.org/10.1093/ecco-jcc/jjx180.622